<?xml version="1.0" encoding="UTF-8"?>
<p>Alzheimerâ€™s disease (AD) is a common neurodegenerative disorder and is mainly characterized by several symptoms such as decline of cognitive function coupled with progressive memory loss. AD is detected by the presence of several molecular lesions that lead to the inflammatory and oxidative damage due to the presence of misfolded proteins accumulated in the aging brain, amounting to synaptic dysfunction and energy loss [
 <xref rid="ref001" ref-type="bibr">1</xref>]. Globally, over 24 million people are estimated to have dementia, of who a majority suffer from AD. Thereby imperatively prioritizing AD research, which represents a major public health concern. As of today, the treatments available focus on reducing the symptoms of AD. Implying the need to understand better the disease pathogenesis in an attempt to discover/develop the kind of treatment that could subside the symptoms or repair the done damage [
 <xref rid="ref002" ref-type="bibr">2</xref>]. Age remains the main risk factor associated with the AD; with most of victims aged over 65 years [
 <xref rid="ref003" ref-type="bibr">3</xref>]. Early diagnosis and investigation remain the most crucial factor to focus the therapeutic ventures involving both pharmaceutical and psychosocial support systems.
</p>
